Testing a new drug combo for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell lung cancer that was confirmed by a biopsy.
- You completed at least 4 cycles (but no more than 6) of first treatment with chemotherapy plus either atezolizumab or durvalumab, and your cancer either shrank or stayed stable.
- You are 18 years or older.
- You weigh at least 50 kg (about 110 pounds).
- You can swallow pills.
- You have adequate organ function (kidney, liver, blood cells) as shown by recent lab tests.
- Brain metastases are allowed if they are treated and stable (no increasing steroids needed) or are very small and not causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a new combination of two drugs (valemetostat and atezolizumab) for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. The goal is to see if adding valemetostat can keep the cancer from growing longer.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Hear when a new Extensive Stage Lung Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.